Phenocopying CHD1 loss, SPOP mutations also cause genomic instability and impaired HR DSB repair, as well as promote the sensitivity of prostate tumors to DNA-damaging therapeutic agents, such as PARP inhibitors (94, 104, 105). This evidence concerns the gene CHD1 and prostate neoplasm.